INCY vs. JNJ: Incyte vs. Johnson & Johnson Stock Comparison

November 11, 2026

How do Incyte (INCY) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Incyte (INCY) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Company profile comparison for Incyte (INCY) and Johnson & Johnson (JNJ)
Profile Item	INCY	JNJ
Name	Incyte Corp.	Johnson & Johnson
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	24.39 billion USD	664.95 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	November 4, 1993	January 2, 1962
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INCY

JNJ

GSPC

Incyte (INCY) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Incyte (INCY) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Incyte (INCY) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Total Return (1Y)	14.06%	53.82%
Total Return (3Y, Annualized)	32.03%	27.51%
Total Return (5Y, Annualized)	12.69%	14.71%

Risk Profile

Drawdown History

INCY

JNJ

GSPC

Incyte (INCY) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Incyte (INCY) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Volatility (1Y, Annualized)	33.19%	21.23%
Beta (5Y)	0.78	0.21
Max Drawdown (5Y)	-40.50%	-18.41%
Avg. Volume (3M)	1.58M	6.93M

Risk-Adjusted Performance

Risk-Return Positioning

INCY and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Sharpe Ratio (1Y)	0.29	2.33
Sortino Ratio (1Y)	0.46	3.66

Profitability

ROE (TTM)

Both Incyte (INCY) at 7.84% and Johnson & Johnson (JNJ) at 20.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max: 109.18%
INCY: 7.84%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max: 109.18%
JNJ: 20.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Incyte (INCY) at 6.71% and Johnson & Johnson (JNJ) at 16.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max: 18.05%
INCY: 6.71%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max: 18.05%
JNJ: 16.20%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Incyte (INCY) at 33.72% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max: 83.12%
INCY: 33.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 83.12%
JNJ: 25.74%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
ROE (TTM)	7.84%	20.02%
ROA (TTM)	17.78%	8.46%
Net Margin (TTM)	6.71%	16.20%
Operating Margin (TTM)	33.72%	25.74%
Gross Margin (TTM)	56.02%	67.78%

Growth

Revenue Growth

Both Incyte (INCY) at 21.22% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both companies show strong earnings momentum, but Incyte (INCY) at 4,173.33% is the standout with EPS growth above its industry range; Johnson & Johnson (JNJ) at 90.50% also sits in the top quartile.

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Revenue Growth (YoY)	21.22%	6.05%
Revenue Growth (3Y CAGR)	14.84%	5.60%
EPS Growth (YoY)	4,173.33%	90.50%
EPS Growth (3Y CAGR)	61.56%	17.90%

Financial Strength

Current Ratio (MRQ)

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max: 25.13
Q3: 12.13
Median: 5.52
INCY: 3.84
Q1: 2.47
Min: 0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
JNJ: 1.02
Min: 0.10

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Johnson & Johnson (JNJ) at 0.55 runs a more typical debt-to-equity mix.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
INCY: 0.01
Min: 0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max: 1.42
Q3: 0.65
JNJ: 0.55
Median: 0.15
Q1: 0.02
Min: 0.00

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Current Ratio (MRQ)	3.84	1.02
Debt / Equity (MRQ)	0.01	0.55
Net Debt / EBITDA	-1.88	0.79

Dividends

Dividend Yield (TTM)

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ: 1.94%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ: 80.12%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
Dividend Yield (TTM)	0.00%	1.94%
Dividend Payout Ratio (TTM)	0.00%	80.12%

Valuation

P/E Ratio (TTM)

Johnson & Johnson (JNJ) at 41.92 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max: 85.34
INCY: 61.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max: 85.34
Q3: 43.46
JNJ: 41.92
Median: 26.69
Q1: 13.30
Min: 0.07

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Incyte (INCY) at 4.06 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max: 58.18
Q3: 25.77
Median: 7.30
INCY: 4.06
Q1: 3.01
Min: 0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 58.18
Q3: 25.77
Median: 7.30
JNJ: 6.69
Q1: 3.01
Min: 0.01

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max: 13.53
Q3: 6.54
INCY: 4.33
Median: 3.25
Q1: 1.69
Min: -5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 13.53
JNJ: 8.16
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Incyte (INCY) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Incyte (INCY) and Johnson & Johnson (JNJ)
Metric	INCY	JNJ
P/E Ratio (TTM)	61.05	41.92
P/S Ratio (TTM)	4.06	6.69
P/B Ratio (MRQ)	4.33	8.16
Free Cash Flow Yield (TTM)	5.28%	2.78%